Peking University Cancer Hospital & Institute: all 266 studies

Page 1 of 3. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.

• SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Phase 2
• A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaNot yet recruitingNCT07854522Phase 4
• Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesRecruitingNCT07848243Phase 2
• Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07843303Phase 2
• Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal CancerRecruitingNCT07833319Phase 2
• Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and SurgeryNot yet recruitingNCT07822906
• Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited MetastasesNot yet recruitingNCT07815288Phase 2
• SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary NodesNot yet recruitingNCT07791771
• 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian CancerNot yet recruitingNCT07790939Early Phase 1
• NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal CancersNot yet recruitingNCT07775859
• 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring ImmunotherapyRecruitingNCT07724535Phase 1/2
• SHR-A1904 in Advanced Colorectal Cancer: an Exploratory StudyNot yet recruitingNCT07700719Phase 2
• Development and Validation of a Colorectal Cancer Diagnostic ModelNot yet recruitingNCT07692555
• Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and VomitingNot yet recruitingNCT07692451Phase 2
• Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI CancersNot yet recruitingNCT07656740
• Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
• Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal CancersNot yet recruitingNCT07642323
• 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid TumorsNot yet recruitingNCT07639801Not applicable
• Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaNot yet recruitingNCT07622706Phase 2
• Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant TherapyNot yet recruitingNCT07599137Phase 4
• Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair DeficiencyNot yet recruitingNCT07595523Phase 2
• Clinical Application of CAIX-Targeted PET Imaging in TumorsRecruitingNCT07590310Early Phase 1
• 5T4 Targeting Nanobody Probe for PET Imaging in Solid TumorsNot yet recruitingNCT07589101Not applicable
• Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNot yet recruitingNCT07567326Phase 2
• Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal CancerNot yet recruitingNCT07552207Not applicable
• Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid TumorsRecruitingNCT07529002
• Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingNCT07527806Phase 2
• Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNot yet recruitingNCT07470203
• PD-L1 Targeting Peptide Probe for PET Imaging of Solid TumorNot yet recruitingNCT07442292
• SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingNCT07417241Phase 2
• A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line TreatmentRecruitingNCT07413042Phase 1
• Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal CancerNot yet recruitingNCT07394192Phase 2
• CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal CancerNot yet recruitingNCT07383285Phase 2
• Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT AloneNot yet recruitingNCT07381543Phase 2
• Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal CancerNot yet recruitingNCT07366047Not applicable
• Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNot yet recruitingNCT07357532Phase 2
• Standardized Management of Esophageal Fistula in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07353541
• Hand and Foot Bath for Taxane-Induced Peripheral NeurotoxicityNot yet recruitingNCT07344974Phase 4
• Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNot yet recruitingNCT07298148Phase 2
• Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World StudyRecruitingNCT07251868
• Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT07241819Phase 2
• Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLCNot yet recruitingNCT07200154Phase 2
• High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNot yet recruitingNCT07182708Phase 2
• Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of StomachRecruitingNCT07178340Phase 2
• A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain MetastasesNot yet recruitingNCT07177950Phase 1/2
• Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATSNot yet recruitingNCT07177924Not applicable
• A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingNCT07165418Phase 3
• Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-MonitorNot yet recruitingNCT07152535
• Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI ClassificationNot yet recruitingNCT07111429
• Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI FailureRecruitingNCT07087223Phase 1/2
• QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07049185Phase 2
• Trop-2 Targeted PET Probes in Advanced TNBCRecruitingNCT07046455Not applicable
• Evaluating AI and Human Expert Decisions in Colorectal CancerNot yet recruitingNCT07045207
• Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLMNot yet recruitingNCT07031570
• Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen PathologyNot yet recruitingNCT07029646Not applicable
• JWCAR239 in Patients With B Cell Non-Hodgkin LymphomaNot yet recruitingNCT07024147Phase 1
• Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingNCT07007728Phase 2
• Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung CancerNot yet recruitingNCT07004712Phase 2
• A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaRecruitingNCT07000617Phase 2
• Perioperative Treatment of Hepatoid Adenocarcinoma of StomachRecruitingNCT06992362Phase 2
• Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker ExplorationRecruitingNCT06991790
• A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
• Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung CancerRecruitingNCT06926179
• Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRDRecruitingNCT06924710Not applicable
• Al18F-HER2-BCH PET in Breast Patients Treated With ADC TherapyRecruitingNCT06909604Not applicable
• Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.RecruitingNCT06894797Not applicable
• Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid BiopsyRecruitingNCT06869239
• A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
• A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous CarcinomaRecruitingNCT06869213Phase 2
• Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLCRecruitingNCT06849167Phase 2
• Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung CancerNot yet recruitingNCT06784206Phase 2
• Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDNot yet recruitingNCT06780839Phase 2
• Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingNCT06768307Phase 2
• Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingNCT06757387Phase 1/2
• TF-antigen Targeting Molecular Probe for PET Imaging in Solid TumorsNot yet recruitingNCT06755086
• Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical CancerNot yet recruitingNCT06745219Phase 2
• A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-NensRecruitingNCT06732505Phase 1
• A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid TumorsRecruitingNCT06728189Phase 1
• CD147 Targeting Peptide Probe for PET Imaging in Solid TumorsNot yet recruitingNCT06720298
• MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid TumorsRecruitingNCT06719856
• 68Ga-HSA PET/CT Imaging for Protein-losing EnteropathyNot yet recruitingNCT06716788
• Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular ImagingRecruitingNCT06715020Not applicable
• Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLCNot yet recruitingNCT06690541
• A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical SurgeryRecruitingNCT06674252Not applicable
• Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung LesionsRecruitingNCT06648317
• EGFR Mutation Targeting Molecular Probe for PET ImagingNot yet recruitingNCT06641674
• The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal CancerNot yet recruitingNCT06609434Not applicable
• The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI DrugsRecruitingNCT06583369Not applicable
• A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic TherapyRecruitingNCT06549907
• HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADCRecruitingNCT06548529Not applicable
• A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell CarcinomaNot yet recruitingNCT06472895Phase 1/2
• Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid TumorsRecruitingNCT06454955Early Phase 1
• Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal CancerNot yet recruitingNCT06443671Phase 2/3
• Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe.Not yet recruitingNCT06435741Not applicable
• A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
• RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 ExpressionRecruitingNCT06420973Phase 2
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
• A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06313957Phase 1
• Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric CancerRecruitingNCT06306755Not applicable
• Hyper-ERAS Program for Highly Selective Colorectal Cancer PatientsRecruitingNCT06256315Not applicable

← Peking University Cancer Hospital & Institute overview and focus areas